Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Cash from Operations (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Cash from Operations for 7 consecutive years, with 5751000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Cash from Operations rose 23.22% to 5751000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was 33072000.0, a 30.13% increase, with the full-year FY2024 number at 33072000.0, up 30.13% from a year prior.
  • Cash from Operations was 5751000.0 for Q4 2024 at Actinium Pharmaceuticals, up from 11975000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 27918000.0 in Q2 2022 to a low of 15077000.0 in Q1 2023.
  • A 4-year average of 5789312.5 and a median of 6577500.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: surged 709.03% in 2022, then tumbled 160.8% in 2023.
  • Actinium Pharmaceuticals' Cash from Operations stood at 5052000.0 in 2021, then tumbled by 53.96% to 7778000.0 in 2022, then rose by 3.7% to 7490000.0 in 2023, then rose by 23.22% to 5751000.0 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Cash from Operations are 5751000.0 (Q4 2024), 11975000.0 (Q3 2024), and 7972000.0 (Q2 2024).